← Back to Search

Receptor Tyrosine Kinase Inhibitor

SLC-391 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by SignalChem Lifesciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new drug, SLC-391, to see if it is safe and effective against advanced solid tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose of SLC-391
Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0
Secondary outcome measures
Area under the plasma concentration versus time curve (AUC) of SLC-391
Maximum Observed Plasma Concentration (Cmax)
Number of Participants with Clinically Significant Changes From Baseline in Laboratory Parameters
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose escalationExperimental Treatment1 Intervention
The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented. A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SLC-391
2022
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

SignalChem Lifesciences CorporationLead Sponsor
3 Previous Clinical Trials
150 Total Patients Enrolled
Zaihui Zhang, PhDStudy DirectorSignalChem Lifesciences Corporation
1 Previous Clinical Trials
98 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Princess Margaret Cancer Centre
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Safety Study of SLC-391 in Subjects With Solid Tumors
2019. "Safety Study of SLC-391 in Subjects With Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03990454.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top